期刊
ONCOLOGIST
卷 22, 期 6, 页码 680-693出版社
WILEY
DOI: 10.1634/theoncologist.2016-0318
关键词
Immunotherapy; Head and neck squamous cell carcinoma; Lymphocyte; Neoplasm of head and neck
类别
资金
- AstraZeneca/MedImmune
- Bristol-Myers Squibb
- Merck
- VentiRX
Advances in the field of cancer immunotherapy have occurred rapidly over the past decade. Exciting results from clinical trials have led to new treatment options and improved survival for patients with a myriad of solid tumor pathologies. However, questions remain unanswered regarding duration and timing of therapy, combination regimens, appropriate biomarkers of disease, and optimal monitoring of therapeutic response. This article reviews emerging immunotherapeutic agents and significant clinical trials that have led to advancements in the field of immuno-oncology for patients with head and neck squamous cell carcinoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据